H J Braam1, J H Schellens2, H Boot3, J W van Sandick4, C A Knibbe5, D Boerma6, B van Ramshorst6. 1. Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. Electronic address: H.Braam@antoniusziekenhuis.nl. 2. Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Science Faculty, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. 3. Division of Gastroenterology and Hepatology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands. 6. Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands.
Abstract
PURPOSE: Several studies have shown the potential benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients. At present the most effective chemotherapeutic regime in HIPEC for gastric cancer is unknown. The aim of this review was to provide a comprehensive overview of chemotherapeutic agents used for HIPEC in gastric cancer. METHODS: A literature search was conducted using the PubMed database to identify studies on chemotherapy used for HIPEC in gastric cancer patients. RESULTS AND CONCLUSION: The chemotherapeutic regime of choice in HIPEC for gastric cancer has yet to be determined. The wide variety in studies and study parameters, such as chemotherapeutic agents, dosage, patient characteristics, temperature of perfusate, duration of perfusion, carrier solutions, intraperitoneal pressure and open or closed perfusion techniques, warrant more experimental and clinical studies to determine the optimal treatment schedule. A combination of drugs probably results in a more effective treatment.
PURPOSE: Several studies have shown the potential benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancerpatients. At present the most effective chemotherapeutic regime in HIPEC for gastric cancer is unknown. The aim of this review was to provide a comprehensive overview of chemotherapeutic agents used for HIPEC in gastric cancer. METHODS: A literature search was conducted using the PubMed database to identify studies on chemotherapy used for HIPEC in gastric cancerpatients. RESULTS AND CONCLUSION: The chemotherapeutic regime of choice in HIPEC for gastric cancer has yet to be determined. The wide variety in studies and study parameters, such as chemotherapeutic agents, dosage, patient characteristics, temperature of perfusate, duration of perfusion, carrier solutions, intraperitoneal pressure and open or closed perfusion techniques, warrant more experimental and clinical studies to determine the optimal treatment schedule. A combination of drugs probably results in a more effective treatment.
Authors: Beate Rau; Linda Feldbrügge; Felix Gronau; Miguel Enrique Alberto Vilchez; Peter Thuss-Patience; Pierre Emmanuel Bonnot; Olivier Glehen Journal: Visc Med Date: 2022-02-23
Authors: Rosa T van der Kaaij; Hidde Jw Braam; Henk Boot; Maartje Los; Annemieke Cats; Cecile Grootscholten; Jan Hm Schellens; Arend Gj Aalbers; Alwin Dr Huitema; Catherijne Aj Knibbe; Djamila Boerma; Marinus J Wiezer; Bert van Ramshorst; Johanna W van Sandick Journal: JMIR Res Protoc Date: 2017-07-13
Authors: W J Koemans; R T van der Kaaij; H Boot; T Buffart; A A F A Veenhof; K J Hartemink; C Grootscholten; P Snaebjornsson; V P Retel; H van Tinteren; S Vanhoutvin; V van der Noort; A Houwink; C Hahn; A D R Huitema; M Lahaye; M Los; P van den Barselaar; O Imhof; A Aalbers; G M van Dam; B van Etten; B P L Wijnhoven; M D P Luyer; D Boerma; J W van Sandick Journal: BMC Cancer Date: 2019-05-06 Impact factor: 4.430